OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian CancerTopline results to be presented by Alexandra Leary, MD, PhD, on May 30, 2026, at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago OSE Immunotherapeutics to host a KOL webcast on June 10, 2026Nantes, France, May 22, 2026 – 7:30am CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announced the release of the abstract selected for an oral presentation at the upcoming ASCO 2026Annual Meeting, unveiling topline results from the TEDOVA/GINECO-OV244b/ENGOT-ov58 academic, international, Phase 2 trial sponsored by ARCAGY-GINECO and evaluating...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR22 MAY 2026 RICHEMONT ANNOUNCES THE END OF THE SHARE BUYBACK PROGRAMME INITIATED IN MAY 2023 AND THE LAUNCH OF A NEW PROGRAMME   Richemont’s three-year share buyback programme announced on 12 May 2023 expired on 21 May 2026. Under the programme, the Company repurchased a total of 2’195’000 ‘A’ shares, representing 0.37% of the capital and 0.20% of the voting rights of Compagnie Financière Richemont SA. Richemont’s share purchase history can be found on the Company’s website at: https://www.richemont.com/investors/shareholder-information/share-buybacks/ In addition, Richemont announces a new programme starting 26 May 2026 to buy back up to 10 million ‘A’ shares, representing 1.69% of the capital and 0.93% of the voting rights of the Company. Purchases will be effected through ‘A’ share purchases...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR22 MAY 2026 RICHEMONT PUBLISHES FY26 ANNUAL REPORT AND ACCOUNTSRichemont has today published its Annual Report and Accounts for the year ended 31 March 2026. The Annual Report includes the Chairman’s review to shareholders, the annual consolidated and statutory financial statements, and the corresponding audit reports. It reflects the information provided in Richemont’s full-year 2026 results announcement issued today. Richemont expects to publish the combined Annual Report with the Compensation Report, the Corporate Governance Report and the Business review for the year ended 31 March 2026, on 29 May 2026. At that time, it will also publish the Richemont Non-Financial Report 2026. The Annual Report is available for download on the Company’s website athttps://www.richemont.com/media/045hlucv/richemont-fy26-annual-report-and-accounts.pdf About...

Provides immediate new financing to support the Company’s next strategic milestones Strengthens shareholders’ equity and improves the Company’s financial structure Supports the continuation of ZEPIZURE® regulatory activities, including upcoming EUA-related steps, and the ramp-up of production readiness throughout 2026 May provide additional funding upon exercise of the warrants Total subscription price of €2.33 per unit, including approximately €1.704 for the share component and €0.626 for the warrant componentDIJON, FRANCE, May 22, 2026 – 07h30 (CET) – CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceutical company developing products for emergency situations based on its proprietary ZENEO® needle-free auto-injector technology, currently in the advanced stages of development and registration for ZEPIZURE®, an...

PRESS RELEASEMay 22, 2026RENAULT GROUP SUCCESSFULLY ISSUES DUAL-TRANCHE SAMURAI BONDS FOR A NOMINAL AMOUNT OF ¥159 BILLION Boulogne-Billancourt, May 22nd, 2026 – Renault Group announces the successful issuance of dual-tranche Samurai bonds for a total nominal amount of ¥159 billion. The transaction is structured as follows:a tranche dedicated to retail investors for an amount of ¥100 billion, maturing in 2030 and carrying a coupon of 3.02%; a tranche dedicated to institutional investors for an amount of ¥59 billion, maturing in 2030 and carrying a coupon of 3.02%.This transaction represents Renault Group’s inaugural issuance featuring both a retail investor tranche and an institutional investor tranche. With this achievement, Renault Group sets a new benchmark as the first non-domestic corporate to launch a dual-tranche Retail...

FRONTLINE PLC REPORTS RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026 Frontline plc (the “Company”, “Frontline,” “we,” “us,” or “our”), today reported unaudited results for the three months ended March 31, 2026: HighlightsProfit of $559.1 million, or $2.51 per share for the first quarter of 2026. Adjusted profit of $344.9 million for the first quarter of 2026, the strongest since the fourth quarter of 2004, or $1.55 per share. Declared a cash dividend of $1.55 per share for the first quarter of 2026. Reported revenues of $714.2 million for the first quarter of 2026. Achieved average daily spot time charter equivalent earnings (“TCEs”)1 for VLCCs, Suezmax tankers and LR2/Aframax tankers in the first quarter of $103,500, $72,400 and $50,700 per day, respectively. Delivered eight of our oldest first-generation ECO VLCCs,...

 VALLOUREC AND SYNGULAR SOLUTIONS SIGN A MEMORANDUM OF UNDERSTANDING TO ACCELERATE THE DEVELOPMENT OF BIOENERGY WITH CARBON CAPTURE AND STORAGE PROJECTS Meudon (France), on May 22, 2026 – Vallourec, a world leader in premium seamless tubular solutions, announces the signing of a Memorandum of Understanding (MoU) with Syngular Solutions, Brazil’s leading engineering and consulting company specialized in Bioenergy with Carbon Capture and Storage (BECCS) and Carbon Capture Utilization and Storage (CCUS) projects, to collaborate on carbon capture and geological storage initiatives in Brazil. This agreement establishes a joint collaboration framework aimed at developing BECCS projects, a carbon removal technology that captures CO₂ from biomass-based energy systems and stores it permanently. This partnership with Syngular Solutions enables Vallourec...

PERTH, Australia, May 21, 2026 (GLOBE NEWSWIRE) — Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO) (OTCQX: NSRPF) reports that all resolutions proposed to shareholders at the annual general meeting of shareholders (held on May 21, 2026 (Vancouver, BC)/May 22, 2026 (Perth, WA)) were approved, including the election of all of the director nominees listed in the management information circular for the meeting. Voting as to each of the director nominees was as follows:Name of Nominee Votes CastFOR % Votes CastFOR VotesWITHHELD % of VotesWITHHELDQuinton Hennigh 97,786,856 97.780 2,219,671 2.220Greg Jones 98,158,880 98.152 1,847,647 1.848Karen O’Neill 98,136,879 98.130 1,869,648 1.870Michael Spreadborough 97,354,477 97.348 2,652,050 2.652Refer to the report of voting results filed under Novo’s profile...

VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) — NervGen Pharma Corp. (“NervGen” or the “Company”) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions, today announced the pricing of an underwritten public offering of 24,000,000 common shares and accompanying warrants to purchase up to 24,000,000 common shares. The common shares are being sold at a public offering price of US$2.50 per common share and accompanying warrant. Each accompanying warrant has an exercise price of US$3.68 per common share, and will be immediately exercisable from the date of issuance, and will expire five years from the date of issuance. All of the securities are being offered by NervGen. The securities...

BEIJING, May 21, 2026 (GLOBE NEWSWIRE) — Yimutian Inc. (Nasdaq: YMT) (“Yimutian” or the “Company”), a leading agricultural digital service company in China, today announced that it has formally submitted a hearing request to the Hering Panel (the “Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) on May 20, 2026, Eastern Time. As previously disclosed, on May 13, 2026, the Company received (i) a notification regarding its deficiency under the Minimum Market Value of Listed Securities (MVLS) requirement pursuant to Nasdaq Listing Rule 5450(b)(2)(A), and (ii) a Determination Letter notifying the Company of its non-compliance with the Minimum Market Value of Publicly Held Shares (MVPHS) requirement under Nasdaq Listing Rule 5450(b)(2)(C), and that it is subject to delisting. In response, the Company timely submitted the hearing request...